Regulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Bromine is significantly less abundant in the crust than fluorine or chlorine, comprising only 2.5 parts per million of the Earth's crustal rocks, and then only as bromide salts. It is significantly more abundant in the oceans, resulting from long-term leaching. There, it makes up 65 parts per million, corresponding to a ratio of about one bromine atom for every 660 chlorine atoms. Salt lakes and brine wells may have higher bromine concentrations: for example, the Dead Sea contains 0.4% bromide ions. It is from these sources that bromine extraction is mostly economically feasible. Bromine is the tenth most abundant element in seawater. The main sources of bromine production are Israel and Jordan. The element is liberated by halogen exchange, using chlorine gas to oxidise Br− to Br2. This is then removed with a blast of steam or air, and is then condensed and purified. Today, bromine is transported in large-capacity metal drums or lead-lined tanks that can hold hundreds of kilograms or even tonnes of bromine. The bromine industry is about one-hundredth the size of the chlorine industry. Laboratory production is unnecessary because bromine is commercially available and has a long shelf life.
== Characteristics == The genome of C. xerosis is approximately 2.7 million base pairs long with over 2,000 genes encoding proteins and a high G+C content. C. xerosis was found to contain a series of plasmids, one of which confers resistance to common antibiotics such as chloramphenicol, kanamycin, streptomycin, and tetracycline and was named pTP10. This plasmid has since been introduced into Bacillus subtilis and modified to generate several vectors for molecular cloning purposes. In addition to having resistance to many antibiotics itself, at least one strain of C. xerosis also appears capable of producing antimicrobial compounds. These can inhibit bacteria and fungi, but the strength of antimicrobial activity by this strain depends on the carbon sources available. Also, a petroleum ether extract from C. xerosis was found to decrease the growth rate of tumors in mice, increasing their lifespan while being nontoxic to healthy mice. A study in 1967 confirmed the ability of several strains of C. xerosis to form single-layer "clumps" of cells around gas bubbles when cultures of the bacteria are suspended in buffer solutions at low temperatures with vigorous stirring. This property was attributed to cell surface proteins.
=== 2025 bankruptcy === In June 2024, Hooters of America abruptly closed approximately 40 locations that were deemed underperforming, blaming rising costs and a decline in sales as part of the decision. On February 21, 2025, it was reported that Hooters of America was preparing to file for Chapter 11 bankruptcy protection within the coming months after prior closures in 2024 and revenue losses at its locations. On March 31, 2025, Hooters of America filed for Chapter 11 bankruptcy protection in an effort to move forward with a sale to franchisees that consists of all of its company-owned restaurants. The company initially had no plans to close restaurants and would remain operational during the procedure. At the time of the bankruptcy, there were 305 Hooters restaurants globally, including 151 restaurants operated by Hooters of America. However, by June 4, 2025, over 30 locations in 12 states permanently closed. Per-store sales at Hooters of America-owned restaurants were less than half those operated by the Clearwater-based company. Overall sales at Hooters of America shrank from $1.2 billion in 2009 to $678 million in 2024. Real American Beer co-founder Hulk Hogan expressed interest in the company acquiring Hooters out of bankruptcy prior to his death in July 2025. The Clearwater-based company, along with a group of other franchisees, purchased the Atlanta-based company out of bankruptcy in October 2025.
Acetyl-S-ACP:malonate ACP transferase (EC 2.3.1.187, acetyl-S-ACP:malonate ACP-SH transferase, acetyl-S-acyl-carrier protein:malonate acyl-carrier-protein-transferase, MdcA, MadA, ACP transferase, malonate/acetyl-CoA transferase, malonate:ACP transferase, acetyl-S-acyl carrier protein:malonate acyl carrier protein-SH transferase) is an enzyme with systematic name acetyl-(acyl-carrier-protein):malonate S-(acyl-carrier-protein)transferase. This enzyme catalyses the following chemical reaction
With the release of Half-Life 2 in 2004, Valve re-released several of its previous titles, ported to their new Source game engine, including the critically acclaimed 1998 game Half-Life as Half-Life: Source. The Source engine is graphically more advanced than the GoldSrc engine used for the original games. Half-Life: Source features the Havok physics engine and improved effects for water and lighting. The level architecture, textures, and models of the game, however, remained unchanged. Half-Life: Source was met with mixed reviews. IGN liked the new user interface and other technical features, but noted that it did not receive as many improvements as Valve's other Source engine ports. GameSpy said that while it was a "fun little bonus", it was "certainly not the major graphical upgrade some people thought it might be". Valve's managing director Gabe Newell is quoted as saying that a complete Source remake of Half-Life by its fans was "not only possible…but inevitable". Black Mesa began as the combination of two independent volunteer projects, each aiming to completely recreate Half-Life using Source. The mod Leakfree was announced in September 2004, and the Half-Life: Source Overhaul Project was announced one month later. After realizing their similar goals, project leaders for both teams decided to combine their efforts; they formed a new 13-person team under the name Black Mesa: Source.
Sources: en.wikipedia.org
== Medical uses == Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. Stimulants produce a noticeable crash or comedown at the end of their effects. In the US, the most frequently prescribed stimulants as of 2013 were lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and amphetamine (Adderall). It was estimated in 2015 that the percentage of the world population that had used cocaine during a year was 0.4%. For the category "amphetamines and prescription stimulants" (with "amphetamines" including amphetamine and methamphetamine) the value was 0.7%, and for MDMA 0.4%. Stimulants have been used in medicine for many conditions including obesity, sleep disorders, mood disorders, impulse-control disorders, asthma, nasal congestion and, in case of cocaine, as local anesthetics. Drugs used to treat obesity are called anorectics and generally include drugs that follow the general definition of a stimulant, but other drugs such as cannabinoid receptor antagonists also belong to this group. Eugeroics are used in management of sleep disorders characterized by excessive daytime sleepiness, such as narcolepsy, and include stimulants such as modafinil and pitolisant. Stimulants are used in impulse control disorders such as ADHD and off-label in mood disorders such as major depressive disorder to increase energy, focus, and elevate mood.
Martin Bright (born 5 June 1966); worked for the BBC World Service and The Guardian; political editor of New Statesman, The Spectator, The Jewish Chronicle's political editor and worked at Tony Blair Faith Foundation; has closely monitored rise of Muslim extremism, terrorist attacks in Britain and abroad, and aspects of British governmental relations with Muslim community in the United Kingdom; founded New Deal of the Mind, a charitable company to promote employment in creative fields and working with organisations, government and all political parties. In 2001, wrote "The Great Koran Con Trick" in the New Statesman and in Channel Four documentary, Who Speaks for Muslims? (2002), and When Progressives Treat with Reactionaries: The British State's flirtation with radical Islamism (2006), a report for the Policy Exchange, Bright examined issues of contemporary Muslim community in the United Kingdom. Tom Brook (born 16 June 1953); broadcaster and journalist working primarily for BBC News, BBC World News, BBC News Channel and Talking Movies. Brook's parents were Caspar Brook, the first director of the Consumers' Association in Britain, and Dinah, journalist for The Observer. Tina Brown, Christina Hambley Brown, Lady Evans (born 21 November 1953), is an English journalist, magazine editor, columnist, talk-show host, and author of The Diana Chronicles (2007) a biography of Diana, Princess of Wales, The Vanity Fair Diaries (2017) and The Palace Papers (2022).
A radioallergosorbent test (RAST) is a blood test using radioimmunoassay test to detect specific IgE antibodies in order to determine the substances a subject is allergic to. This is different from a skin allergy test, which determines allergy by measuring a person's skin reaction to different substances.
Simulating the systemic environment in tectonic fault zones within the Earth's crust, pressure cycling forms vesicles periodically, as well as random peptide chains which are selected for ability to integrate into the vesicle membrane. Further selection of vesicles for stability could lead to functional peptide structures, increasing vesicle survival rate.
Opium production has led to rising tensions in Afghan villages. Though direct conflict has yet to occur, the opinions of the new class of young rich men involved in the opium trade are at odds with those of the traditional village leaders.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.